Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements

作者：Yongchang Zhang, Zhe Huang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, C. Xu, Jun Liu, Wenxian Wang, Zhengbo Song, Sai‐Hong Ignatius Ou, Nong Yang · 发表于：npj Precision Oncology · 年份：2022 · DOI：10.1038/s41698-022-00264-w · 被引用次数：15 · 研究领域：Lung Cancer Treatments and Mutations、PI3K/AKT/mTOR signaling in cancer、Colorectal Cancer Treatments and Studies

This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.